pp-029 Tablets 40 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
Registered in
South Korea
Comments
For maintenance of healing in erosive esophagitis. Approved in South Korea for erosive esophagitis, with studies showing efficacy as both initial therapy and maintenance. A potassium-competitive acid blocker (P-CAB) which rapidly and durably suppresses gastric acid by reversibly inhibiting the H⁺/K⁺-ATPase in parietal cells;
Manufacturer #7042
A pharmaceutical manufacturer engaged in the research, development, production and global supply of a broad range of pharmaceutical products, including prescription drugs, over-the-counter medicines and biologic therapies in finished dosage forms such as tablets, capsules, ointments, injections and liquids, as well as active pharmaceutical ingredients. The company combines integrated R&D with GMP-compliant manufacturing capabilities and commercial operations to support quality, safety and reliability in its pharmaceutical products for diverse therapeutic needs.